Paindrainer AB enters the U.S. market by successfully securing its first commercial partnership
Paindrainer AB is pleased to announce the formalization of a commercial partnership agreement with Dr. Edward Rubin, Past President of The New York Society of Interventional Pain Physicians. This strategic collaboration accomplishes a crucial milestone, allowing Paindrainer AB access to the U.S. market with its groundbreaking FDA registered Medical Device Class I digital solution for chronic pain management.
Paindrainer AB has persistently focused to achieve an increased presence in the US, now resulting in this crucial strategic milestone securing the entry into the American market.
”I am excited to announce the achievement of the company's most significant commercial milestone to date. The dedication and hard work of our team have resulted in a successful outcome and marks the initiation of our next crucial phase of scaling up across the U.S., which looks very promising. I am excited about the upcoming expansion and what the future holds.”, says Erik Frick, CEO Paindrainer AB.
Dr. Edward Rubin exemplifies a forward-thinking pain specialist. Dr. Rubin did his residency in Anesthesiology at Weill Cornell Hospital in Manhattan. After residency, he attended the Quad Institution Pain Fellowship, training at Weill Cornell, Memorial Sloan Kettering, Hospital for Special Surgery and Columbia Presbyterian Hospitals. Dr Rubin is currently in private practice on Long Island, New York.
“Paindrainer allows pain practitioners the capability to remotely monitor their patient’s progress during treatment. This patient-centric digital tool empowers patients to stay in daily communication with their treating physician. We can only manage what we can measure. The future of health care reimbursement depends on our ability to provide data surrounding our treatment outcomes. In my quest for an advanced digital solution, I am glad to enter a successful partnership with Paindrainer.”, says Dr. Ed Rubin.
Paindrainer® is the first evidence based digital tool demonstrating improved quality of life in patients suffering from chronic pain. The solution is powered by leveraging advanced algorithms and is fully adaptive to each individual patient, a unique feature we call the 360o patient-centricity©. Paindrainer PD1 is an FDA registered Class I Medical Device.
Erik Frick
CEO Paindrainer AB
erik.frick@paindrainer.com
+46 736 612123
Edward Rubin, MD
erubin@edrubinmd.com
About Paindrainer AB
Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. Paindrainer was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors. The idea was born when Maria, after participating in several pain rehabilitation programs, realized that pain is affected by many more factors than the human brain can comprehend.
Paindrainer® is the first evidence-based AI powered digital tool demonstrating improved quality of life in patients suffering from chronic pain.
Paindrainer® coaches the users in managing their pain and planning their day not to exceed a certain pain level, and to ensure that there is enough energy left for highly valued activities. The solution is powered by leveraging advanced algorithms and is fully adaptive to each patient, a feature called 360o patient-centricity©.
Paindrainer® (Paindrainer PD1) is an FDA registered Medical Device Class 1 (510k exemption), MDR compliant and CE certified.
www.paindrainer.com